A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-A1912 for Injection as Monotherapy in Patients With B-cell Lymphoma
Latest Information Update: 04 Jul 2024
At a glance
- Drugs SHR-A1912 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Shanghai Hengrui Pharmaceutical
- 04 Jun 2024 Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 29 Nov 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Mar 2024.
- 11 Jun 2023 Planned number of patients changed from 123 to 170.